Phase II Trial of Natalizumab (Tysabri®) Plus Prednisone for Initial Therapy of Acute Graft Versus Host Disease (aGVHD) of the Gastrointestinal Tract


This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug Natalizumab in treating Acute Graft versus Host Disease in the Gastrointestinal Tract.

Study Start Date

January 2015

Estimated Completion Date

March 2020


  • Drug: Natalizumab
  • Drug: Methylprednisolone


  • Oncology: BMT/SCT,Leukemia/Lymphoma
  • Physician Assistant: Gastroenterology,Hematology/Oncology

MeSH Terms

  • Graft vs Host Disease
  • Methylprednisolone

Study ID

Dana-Farber Cancer Institute -- 14-140



Trial ID


Study Type


Trial Phase

Phase 2

Enrollment Quota



Dana-Farber Cancer Institute

Inclusion Criteria

  • Participants must meet the following criteria on screening examination to be eligible to participate in the study:
  • Participants must have acute GVHD of the lower gastrointestinal tract as defined by the clinical impression of the treating physician, requiring systemic treatment. Minimum criteria for GI GVHD includes diarrhea of greater than 500 mL/day. Biopsy of the GI tract is required for study entry and must confirm the diagnosis of acute GVHD. Stool samples to rule out infectious causes of diarrhea, including norovirus, Clostridium difficile and other clinically indicated infections must also be negative. Eligibility includes:
  • Acute GVHD developing after allogeneic hematopoietic stem cell transplantation (HSCT) using bone marrow, peripheral blood stem cells, or umbilical cord blood. Recipients of non-myeloablative, reduced intensity and myeloablative transplants are eligible.
  • Patients who develop acute GVHD after donor lymphocyte infusion (DLI) are eligible.
  • There is no specified time window after day 0 of transplant as acute GVHD is only defined by clinical manifestations.
  • Patients must have experienced neutrophil engraftment after HSCT as defined by absolute neutrophil counts ? 500 / µL × 3 consecutive measurements. Absolute neutrophil count (ANC) should be calculated using the standard formula (Neut + Bands)(WBC × 101).
  • The presence of hepatic, upper GI and/or cutaneous acute GVHD is permitted.
  • Steroids can be started up to 3 days prior to the administration of natalizumab.
  • Age ? 18
  • Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria
  • Participants who exhibit any of the following conditions at screening will not be eligible for admission into the study:
  • Patients with the entity of Acute/Chronic GVHD overlap syndromes.
  • Requiring mechanical ventilation
  • Vasopressor requirement
  • Concurrent hepatic veno-occlusive disease (VOD) based on clinical examination
  • Karnofsky performance status < 30
  • Participants may not be receiving any other study agents for at least 7 days prior to enrollment
  • Prior use of natalizumab for any reason is not allowed
  • Pregnant women are excluded from this study because of the potential teratogenic effects of natalizumab. Because natalizumab enters breast milk, and the effect is unknown in infants, breastfeeding should be discontinued if the mother is treated with natalizumab.

Exclusion Criteria





18 Years and older

Accepts Healthy Volunteers


Study Locations and Contact Information (2)

Study Location Distance Name Phone Email
DanaFarber Cancer Institute - Boston, Massachusetts 2.6 miles Corey Cutler MD MPH 617-632-3470
Massachusetts General Hospital - Boston, Massachusetts 2.8 miles YiBen Chen MD 617-726-1124 provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.